Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jun 19;36(10):1292–1304. doi: 10.1177/02692155221107090

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 2. — Longitudinal changes in (a) median House-Brackmann 2.0 (FNGS 2.0) and (b) SB synkinesis scores, according to the treatment group for the complete cohort (n = 40). Legend: House-Brackmann 2.0 or FNGS 2.0 synkinesis scores: 4 = severe synkinesis; 0 = no synkinesis. Sunnybrook synkinesis scores: 15 = severe synkinesis; 0 = no synkinesis Assessment times: Flaccid phase = 10–14 days post-onset; paretic phase: 1-, 2-, and 3- months post onset; Synkinetic phase: 4-, 5-, and 6-months post-onset; chronic phase: 1-year post-onset; Black line: MEPP participants; Dash line: Controls. SB: Sunnybrook; MEPP: Mirror Effect Plus Protocol; FNGS: Facial Nerve Grading Scale.